Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits

Szilvássy, Zoltán; Jakab, Iidiko; Bor, P.; Koltai, M.; Tarrade, T; Esanu, André; Braquet, P.; Lonovics, J.

doi:10.1097/00019501-199305000-00008

Cited by 11 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anaesthetized, open-chest, artificially ventilated rabbits were subjected to VOP of 500b.p.m. for 5 min as described (Szilvassy et al, 1993a). Normal and NG-tolerant rabbits were divided into three subgroups.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Loss of preconditioning in rabbits with vascular tolerance to nitroglycerin

Szilvássy

Ferdinándy

Bor

et al. 1994

British J Pharmacology

View full text Add to dashboard Cite

A preceding right ventricular overdrive pacing (VOP) of 500 b.p.m. for 5 min, markedly reduced the severity of global myocardial ischaemia produced by a subsequent 5-min VOP in conscious rabbits. This VOP-induced preconditioning developed in parallel with an increase in cardiac cyclic guanosine 3':5'-monophosphate (cyclic GMP) content. VOP-induced preconditioning was abolished when the animals had been made tolerant to the vasodilator effect of nitroglycerin (NG). In the heart of the NG-tolerant rabbits, neither VOP nor preconditioning increased cyclic GMP content. This suggests that changes by NG tolerance of cyclic GMP metabolism may account for the loss of VOP-induced preconditioning.

show abstract

mentioning

confidence: 99%

“…A group was killed for measuring baseline cyclic GMP values. Cardiac cyclic GMP content was measured by means of radioimmunoassay using Amersham kits as described (Szilvassy et al, 1993a). Data expressed as means ± s.d.…”

mentioning

confidence: 99%

Loss of preconditioning in rabbits with vascular tolerance to nitroglycerin

Szilvássy

Ferdinándy

Bor

et al. 1994

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…The antiischemic effect of CIC was demonstrated in various animal models in which global myocardial ischemia was achieved by the method of complete coronary occlusion 2,3 or rapid pacing. [4][5][6] The antiarrhythmic property of CIC has already been shown by previous studies, the majority of which was performed on isolated heart preparations. [7][8][9] On the other hand, very few studies concerning CIC's antiarrhythmic action were carried out under in vivo conditions.…”

Section: Introductionmentioning

confidence: 76%

“…21 At first, the right ventricular effective refractory period (VERP) was determined as described previously. 4 In brief, electrical square impulses of 1.5-millisecond duration at twice the diastolic threshold were delivered via the implanted electrode by means of the programable stimulator. Single programmed extra stimuli were introduced late in diastole after 12 basic driven beats of 200-millisecond cycle length.…”

Section: The Arrhythmogenesis Protocolmentioning

confidence: 99%

“…4,23 In this case, 10 mg$kg 21 of intravenous diazepam (Seduxen) was used to induce anesthesia, then the trachea was cannulated and 1.5% isoflurane (Forane, Abbott Laboratories, Berkshire, United Kingdom) was administered to complete and maintain general anesthesia using small animal respirator (TSE Systems GmbH, Bad Homburg, Germany). The chest was opened, and the left ventricular sample was rapidly taken and put into liquid nitrogen within 5 seconds for determination of cGMP and cAMP contents 24 by the use of Amersham Biotrak radioimmunoassay systems (Little Chalfont, Buckinghamshire, United Kingdom) as described previously.…”

Section: Cardiac Cyclic Nucleotide Measurementmentioning

confidence: 99%

See 1 more Smart Citation

Beneficial Cardiac Effects of Cicletanine in Conscious Rabbits With Metabolic Syndrome

Drimba

Hegedűs²,

Yin³

et al. 2012

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

In Vivo Preclinical Evaluation of a Promising Antiarrhythmic Agent, EGIS‐7229

Drimba

Németh

Sári

et al. 2012

Drug Development Research

View full text Add to dashboard Cite

Preclinical Research The basic hemodynamic, electrophysiological, and pharmacological effects of EGIS‐7229 (E‐7229) were evaluated and compared with those of a pure “Class III“ antiarrhythmic drug (GLG‐V‐13) in conscious rabbits. Both compounds decreased heart rate dose‐dependently. Mean arterial blood pressure was not influenced by E‐7229; however, GLG‐V‐13 produced a significant elevation on this parameter. Left ventricular end‐diastolic pressure was gradually increased by E‐7229, while GLG‐V‐13 induced more considerable elevation on that at intermediate doses. QT and QTcb were lengthened by both compounds; however, higher doses of E‐7229 resulted in shortening of the prolonged QT and QTcb. Ventricular effective refractory period (VERP) was significantly prolonged by either drug studied. Threshold doses to produce QT50%, QTmax, VERP50%, and VERPmax were significantly higher for E‐7229 compared with GLG‐V‐13. Significantly higher doses were required for E‐7229 to induce arrhythmias. The safety ratio was comparable for both of the compounds. E‐7229 can exert multiple actions on cardiac ion channels with minimal influence on hemodynamic parameters and reduced proarrhytmic profile in our preclinical model.

show abstract

Cicletanine attenuates overdrive pacing-induced global myocardial ischemia in rabbits

Cited by 11 publications

References 0 publications

Loss of preconditioning in rabbits with vascular tolerance to nitroglycerin

Loss of preconditioning in rabbits with vascular tolerance to nitroglycerin

Beneficial Cardiac Effects of Cicletanine in Conscious Rabbits With Metabolic Syndrome

In Vivo Preclinical Evaluation of a Promising Antiarrhythmic Agent, EGIS‐7229

Contact Info

Product

Resources

About